Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study : Episode 3

VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression

April 3, 2025

By Sumanta Pal, MD, FASCO
Benjamin Gerendash, MSN, RN, AGACNP-BC

Opinion

Video

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

EP: 1.First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape

EP: 2.Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy

Now Viewing

EP: 3.VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression

EP: 4.Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC

EP: 5.Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic

EP: 6.TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice

EP: 7.Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2

EP: 8.Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777